Bharat Biotech
Bharat Biotech is a Hyderabad-based, promoter-owned biotechnology company founded in 1996 that develops and manufactures a portfolio of 20+ vaccines and biotherapeutics across five proprietary technology platforms for governments, WHO/UNICEF, and private markets in 125+ countries.
- Company typePrivate
- Founded1996
- HeadquartersHyderabad, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bharat Biotech does
Bharat Biotech International Limited, founded in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, is a Hyderabad-headquartered, entirely promoter-owned biotechnology company that develops and manufactures vaccines and bio-therapeutics. It operates one of India's most comprehensive vaccine portfolios with over 20 vaccines spanning COVID-19 (COVAXIN, iNCOVACC), rotavirus (ROTAVAC, ROTAVAC 5D), typhoid (Typbar TCV, Typbar), cholera (Hillchol), Japanese encephalitis (JENVAC), rabies (Indirab), polio (Biopolio), Hib (BioHib), and combination pediatric products (Comvac 4/5), plus biotherapeutic wound-healing brands (REGEN-D, SLVRGEN). The company's technology stack spans five vaccine platforms: inactivated whole virion, live attenuated, polysaccharide conjugate, recombinant DNA, and viral vector, anchored by proprietary HIMAX technology for cesium chloride-free Hepatitis B and a BSL-3 high-containment facility at Genome Valley that produced COVAXIN at 77.8% efficacy. As of July 2025 the company holds 220+ granted global patents with 415 filings, 9-10 billion cumulative doses delivered, manufacturing across six Indian sites, and active distribution to 125+ countries.
Bharat Biotech firmographics
Firmographics- Name
- Bharat Biotech
- Legal name
- Bharat Biotech International Limited
- Website
- https://bharatbiotech.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Bharat Biotech is a Hyderabad-based, promoter-owned biotechnology company founded in 1996 that develops and manufactures a portfolio of 20+ vaccines and biotherapeutics across five proprietary technology platforms for governments, WHO/UNICEF, and private markets in 125+ countries.
- Ownership category
- akta.pro rank
Bharat Biotech industry classification
Industry- Product category
- Vaccines & Biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Travel & Tropical Disease Vaccines (HLAIAEAE)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ), Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG)
Keywords
Where Bharat Biotech is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices7 records
Markets served
Bharat Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Vaccine Product Sales: Sale of vaccines including COVAXIN, ROTAVAC, Typbar TCV, and other vaccine products to government immunization programs and private markets globally
- Biotherapeutic Products: Sale of biotherapeutic products including REGEN-D for diabetic foot ulcers and burns, and SLVRGEN for wound healing
- Technology Licensing: Licensing of proprietary technologies and manufacturing capabilities to international partners
- CRDMO Services: Contract research, development and manufacturing services through Nucelion Therapeutics for cell and gene therapies
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | COVID-19 intranasal vaccine iNCOVACC pricing tiers |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Bharat Biotech product offering
Product offeringCore offering
Bharat Biotech manufactures and supplies a portfolio of 20+ vaccines and biotherapeutic products, including COVID-19 vaccines (COVAXIN, iNCOVACC), rotavirus vaccines (ROTAVAC, ROTAVAC 5D), typhoid conjugate vaccine (Typbar TCV), cholera vaccine (Hillchol), rabies, polio, Japanese encephalitis, Hib, hepatitis B, and combination pediatric vaccines, along with wound-healing biotherapeutics (REGEN-D, SLVRGEN). The company also operates a CRDMO subsidiary (Nucelion Therapeutics) providing cell and gene therapy contract manufacturing services. Products are sold to government immunization programs and private healthcare markets across 125+ countries.
Product overview
Bharat Biotech is a Hyderabad-based vaccine and biotherapeutics manufacturer established in 1996, operating as a comprehensive product portfolio company with over 20 vaccines and 4 biotherapeutics. The company's vaccine portfolio spans major disease areas including COVID-19 (COVAXIN®, iNCOVACC®), rotavirus (ROTAVAC®, ROTAVAC 5D®), typhoid (Typbar TCV®, Typbar®), cholera (Hillchol®), Japanese encephalitis (JENVAC®), influenza (HNVAC®), rabies (Indirab®), polio (Biopolio®), Hib (BioHib®), and combination pediatric vaccines (Comvac 4®, Comvac 5®). The hepatitis B franchise includes Revac-B mcf® and Revac-B+® using proprietary HIMAX technology. Biotherapeutics include REGEN-D® 150 and 60 (epidermal growth factors for wound healing), SLVRGEN® (burns treatment), and BIOGIT® (probiotic yeast). The company has expanded into cell and gene therapies through its Nucelion Therapeutics subsidiary, representing a post-pandemic strategic pivot. Bharat Biotech delivers approximately 9-10 billion vaccine doses annually to over 125 countries, with manufacturing facilities in Hyderabad, Ankleshwar, Mallur, and Pune, all conforming to USFDA, KFDA, WHO, and other global regulatory standards.
Differentiator
Problem solved
Functional benefit
Brands
- COVAXIN: India's first indigenous COVID-19 vaccine, developed in collaboration with ICMR-NIV
- iNCOVACC
- ROTAVAC
- ROTAVAC 5D
- Typbar TCV
- Hillchol
- JENVAC
- REGEN-D
- Nucelion Therapeutics
Products and services
- COVAXIN
- iNCOVACC (BBV154)
- ROTAVAC
- ROTAVAC 5D
- Typbar TCV
- Typbar
- Hillchol
- JENVAC
- HNVAC
- Indirab
- Biopolio
- BioHib
- Comvac 5
- Comvac 4
- Revac-B mcf
- Revac-B+
- SLVRGEN
- REGEN-D 150
- REGEN-D 60
- BIOGIT
- Nucelion Therapeutics (CRDMO Services)
Quantifiable outcome
- ROTAVAC 5D reduces moderate-to-severe rotavirus diarrhoea hospitalizations in children under five from 36% to 18%
- +2 more outcomes
Companies that use Bharat Biotech
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Bharat Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Bharat Biotech partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered minor and core.
- Evogene LtdminorKey partnership for AI-driven plant genomics targeting sustainable agriculture solutions
- Sagar Defence Engineering Pvt LtdminorBharat Biotech emerged as a key investor supporting maritime innovation project in Andhra Pradesh
- Sapigen Biologix Pvt LtdcoreSubsidiary developing large vaccine manufacturing facility in Bhubaneswar, Odisha with Rs 200-250 crore investment
- Tamil Nadu GovernmentcoreMoU signed for ₹5,000 crore bio-similars manufacturing facility in Kancheepuram district; government facilitating life sciences park development
- Pandorum TechnologiescoreCollaboration with Nucelion Therapeutics (Bharat Biotech subsidiary) to expand manufacturing capabilities for exosome-based therapeutic platform targeting ocular diseases across Asia-Pacific region
- BiofabricoreTechnology transfer agreement for MTBVAC tuberculosis vaccine to support manufacturing and distribution in over 70 countries as part of India's Phase III clinical trial preparations expected to start in early 2026
- Hilleman LaboratoriescorePartnership for launch of Hillchol oral cholera vaccine in India with plans for WHO prequalification for global distribution
- AlopexxcoreCollaboration for development and commercialization of broad-spectrum anti-microbial vaccine AV0328
- GSKcorePartnership to advance development of GSK's Shigella vaccine candidate for severe bacterial diarrhoea; also malaria vaccine RTS,S supply partnership
- Washington University School of MedicinecoreLicensing deal for intranasal COVID-19 vaccine technology advancement
- University of Sydney and ExcellGenecoreCEPI-funded partnership to develop 'variant-proof' COVID-19 vaccine
- Bilthoven Biologicals (Serum Institute)coreCollaboration to produce and supply Oral Polio Vaccines leveraging combined manufacturing capabilities
- OcugencoreCo-development and commercialization of COVAXIN for US market; expanded to include Canada
- Precisa MedicamentoscoreSupply agreement for COVAXIN to Brazil
- GSK, PATHcoreProduct transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
- CEPI and IVIcoreCEPI grant of US$14.1 million for Chikungunya vaccine development in collaboration with Ind-CEPI
Scale indicators6 records
Recent moves9 records
Expansion highlights7 records
Bharat Biotech competitors and assessment
Company assessmentOthers
- Ocugen: US-based biopharmaceutical partner commercializing COVAXIN in the United States and Canada. Channel partner relationship rather than direct competitor, but provides a useful comparable for routes-to-market in regulated Western geographies.
Direct peers
- Biological E: Hyderabad-based Indian vaccine and biologic manufacturer with strong pediatric immunization portfolio including Japanese encephalitis, DPT, and pentavalent vaccines. Comparable as a peer Indian vaccine producer targeting government tenders and emerging-market supply through WHO PQ.
- Panacea Biotec: New Delhi-based Indian vaccine manufacturer with WHO-prequalified products across polio, DPT, and combination pediatric vaccines. Direct competitor for Indian government immunization contracts and emerging-market tenders with overlapping product portfolio.
- Indian Immunologicals: Hyderabad-based Indian vaccine manufacturer (National Dairy Development Board subsidiary) producing rabies, pediatric, and animal vaccines. Direct peer in Indian government immunization supply and rabies market where Bharat Biotech's Indirab competes.
- Serum Institute of India: World's largest vaccine manufacturer by doses, headquartered in Pune, India. Direct competitor across polio, rotavirus, HPV, measles, and pandemic vaccines, supplying UNICEF and GAVI at global scale. Bharat Biotech and SII compete head-to-head for Indian government immunization contracts and WHO PQ supply positions.
Broad incumbents
- GSK: Global vaccine major with established portfolio across pediatric, travel, and adult vaccines including Shigella and RTS,S malaria — both of which are partnered with Bharat Biotech. Broad incumbent serving overlapping disease areas but with much wider geographic and product reach.
- Sanofi Pasteur: Global vaccines division of Sanofi with deep portfolio across pediatric (Hexaxim), influenza, travel, and rabies vaccines. Broader incumbent competitor in higher-margin travel and adult segments; co-markets Shanchol oral cholera vaccine in markets where Bharat Biotech's Hillchol competes.
Emerging players
- Sinovac Biotech: Chinese vaccine manufacturer with WHO-prequalified COVID-19, influenza, and hepatitis vaccines targeting emerging markets. Comparable as an emerging-market vaccine producer competing for WHO PQ supply positions and developing-world immunization tenders.
- Hilleman Laboratories: Singapore-based vaccine developer co-founded by MSD and Wellcome Trust, partnering with Bharat Biotech on Hillchol oral cholera vaccine. Niche player focused on affordable vaccines for developing countries, with overlapping tropical-disease R&D priorities.
- Biofabri: Spanish biopharmaceutical manufacturer that developed MTBVAC tuberculosis vaccine and signed a technology transfer agreement with Bharat Biotech for manufacturing and distribution in 70+ countries. Specialized vaccine developer with overlapping TB pipeline focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Bharat Biotech social profiles
Digital presenceBharat Biotech compliance and trust
Trust signalCompliance8 records
Bharat Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bharat Biotech leadership team
Management profileNumber of profiles
Profiles6 records
Bharat Biotech subsidiaries and ownership
Company hierarchySubsidiaries2 records
Bharat Biotech funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bharat Biotech M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bharat Biotech
What does Bharat Biotech do?
Bharat Biotech manufactures and supplies a portfolio of 20+ vaccines and biotherapeutic products, including COVID-19 vaccines (COVAXIN, iNCOVACC), rotavirus vaccines (ROTAVAC, ROTAVAC 5D), typhoid conjugate vaccine (Typbar TCV), cholera vaccine (Hillchol), rabies, polio, Japanese encephalitis, Hib, hepatitis B, and combination pediatric vaccines, along with wound-healing biotherapeutics (REGEN-D, SLVRGEN). The company also operates a CRDMO subsidiary (Nucelion Therapeutics) providing cell and gene therapy contract manufacturing services. Products are sold to government immunization programs and private healthcare markets across 125+ countries.
Is Bharat Biotech a public or private company?
Bharat Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bharat Biotech founded?
Bharat Biotech was founded in 1996. It employs 1,001 to 5,000 people.
Where is Bharat Biotech based?
Bharat Biotech is headquartered in Hyderabad, India, in the Asia region.
How does Bharat Biotech make money?
Four revenue lines are on record. Vaccine Product Sales are the primary driver. The others are biotherapeutic Products, technology Licensing and CRDMO Services.
Who are Bharat Biotech's main competitors?
Ocugen is listed as an others. Direct peers are Biological E, Panacea Biotec, Indian Immunologicals and Serum Institute of India. Broad incumbents are GSK and Sanofi Pasteur. Emerging players are Sinovac Biotech, Hilleman Laboratories and Biofabri.
Does Bharat Biotech have an API?
No public API is recorded for Bharat Biotech.
What industry is Bharat Biotech in?
Bharat Biotech's product category is Vaccines & Biotherapeutics. Its primary akta.pro industry code is HLAIAEAE, Travel & Tropical Disease Vaccines, with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.